REACH Pharmaceuticals and its licensor MSN Laboratories have received approval to commercialise Nelarabine-Reach 250mg/50ml solution for infusion through 'early access to a medicine under evaluation' for inclusion on the ARTG.
Nelarabine-Reach nelarabine 250mg/50ml solution for infusion is not approved in Australia and remains under evaluation by the TGA for registration.
Supply is authorised under an approval granted by the TGA under Section 19A of the Therapeutic Goods Act 1989.
"This approval of Nelarabine is particularly special for MSN and our partner Reach Pharmaceuticals and is a reflection of our commitment to enhance our offering in this important and niche treatment paradigm that will benefit patients the most, and doctors too in Australia," said MSN's Executive Director Bharat Reddy.
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Oct 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Oct 23
